Selected article for: "age group and independent predictor"

Author: O Gallagher, K.; Shek, A.; Bean, D. M.; Bendayan, R.; Teo, J. T.; Dobson, R. J.; Shah, A. M.; Zakeri, R.
Title: Pre-existing cardiovascular disease rather than cardiovascular risk factors drives mortality in COVID-19
  • Cord-id: ac5xe8mg
  • Document date: 2020_12_4
  • ID: ac5xe8mg
    Snippet: Background The association between cardiovascular (CV) risk factors, such as hypertension and diabetes, established CV disease (CVD), and susceptibility to CV complications or mortality in COVID-19 remains unclear. Methods We conducted a cohort study of consecutive adults hospitalised for severe COVID-19 between 1st March and 30th June 2020. Pre-existing CVD, CV risk factors and associations with mortality and CV complications were ascertained. Findings Among 1,721 patients (median age 71 years,
    Document: Background The association between cardiovascular (CV) risk factors, such as hypertension and diabetes, established CV disease (CVD), and susceptibility to CV complications or mortality in COVID-19 remains unclear. Methods We conducted a cohort study of consecutive adults hospitalised for severe COVID-19 between 1st March and 30th June 2020. Pre-existing CVD, CV risk factors and associations with mortality and CV complications were ascertained. Findings Among 1,721 patients (median age 71 years, 57% male), 349 (20.3%) had pre-existing CVD (CVD), 888 (51.6%) had CV risk factors without CVD (RF-CVD), 484 (28.1%) had neither. Patients with CVD were older with a higher burden of non-CV comorbidities. During follow-up, 438 (25.5%) patients died: 37% with CVD, 25.7% with RF-CVD and 16.5% with neither. CVD was independently associated with in-hospital mortality among patients <70 years of age (adjusted HR 2.43 [95%CI 1.16-5.07]), but not in those [≥]70 years (aHR 1.14 [95%CI 0.77-1.69]). RF-CVD were not independently associated with mortality in either age group (<70y aHR 1.21 [95%CI 0.72-2.01], [≥]70y aHR 1.07 [95%CI 0.76-1.52]). Most CV complications occurred in patients with CVD (66%) versus RF-CVD (17%) or neither (11%; p<0.001). 213 [12.4%] patients developed venous thromboembolism (VTE). CVD was not an independent predictor of VTE. Interpretation In patients hospitalised with COVID-19, pre-existing established CVD appears to be a more important contributor to mortality than CV risk factors in the absence of CVD. CVD-related hazard may be mediated, in part, by new CV complications. Optimal care and vigilance for destabilised CVD are essential in this patient group.

    Search related documents:
    Co phrase search for related documents
    • absence presence and acute heart failure: 1, 2
    • absence presence and acute myocardial infarction: 1, 2
    • absence presence and acute respiratory infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • absence presence and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
    • absence presence and additional effect: 1
    • absence presence and admission time: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • absence presence and liver function: 1, 2
    • absence presence and logistic regression model: 1, 2, 3, 4, 5, 6, 7
    • absence presence and low incidence: 1, 2
    • absence presence and low prevalence: 1, 2, 3, 4
    • absence presence and magnetic resonance: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acei angiotensin converting enzyme inhibitor and acute respiratory infection: 1
    • acei angiotensin converting enzyme inhibitor and acute respiratory syndrome: 1, 2, 3, 4, 5
    • acei angiotensin converting enzyme inhibitor and logistic regression model: 1